benzyl 10-hydroxydecanoate | 67853-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 10-hydroxydecanoate
• 英文别名: Phenylmethyl 10-hydroxydecanoate
• CAS: 67853-00-3
• 化学式: C₁₇H₂₆O₃
• 分子量: 278.392
• InChiKey: BFVRXDFGACELQB-UHFFFAOYSA-N

物化性质

• 沸点：
  389.6±15.0 °C(Predicted)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl 10-hydroxydecanoate 在 四丙基高钌酸铵 、 4 Angstroem MS 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以81%的产率得到benzyl 10-oxodecanoate
  参考文献：
  名称：

  Synthesis and Ring Contraction Reactions of Polyazamacrolides

  摘要：

  The synthesis of three analogues of the single most abundant component of a ladybird beetle (Epilachna borealis) defensive secretion, the trimeric 42-membered polyazamacrolide PAML 681, is described. Construction of the nonnatural macrocyclic trimers began with the preparation of the corresponding monomeric segments, followed by their oligomerization and a final macrolactonization step of the activated linear trimeric hydroxy acid. The relative rates of the O-to-N acyl migrations that are characteristic of PAML 681 itself, as well as of the synthetic analogues, were investigated. These studies showed that changes in the substitution pattern adjacent to the nucleophilic nitrogen atom, along with changes in the size of the oxaazacyclic intermediates, have substantial effects on the polyazamacrolide rearrangement rates.

  DOI：

  10.1021/jo001247h
• 作为产物：
  描述：

  benzyl 10-undecenoate 在 dimethyl sulfide borane 、 臭氧 作用下， 生成 benzyl 10-hydroxydecanoate
  参考文献：
  名称：

  A convenient method for the reduction of ozonides to alcohols with borane-dimethyl sulfide complex

  摘要：

  DOI：

  10.1021/jo00267a035

文献信息

• Stable fragrance microcapsule suspension and process for using same
  申请人：Lee Kaiping

  公开号：US20050227907A1

  公开（公告）日：2005-10-13

  Described is a stable initial impact and continuous impact fragrance and/or benefit agent-imparting aqueous suspension of microencapsulated fragrance and/or benefit agent, e.g., malodour counteractant suspended in a non-confined fragrance-containing and/or benefit agent-containing liquid phase oil-in-water emulsion. On storage, the viscosity of the suspension undergoes a minimal increase over an extended period of time thereby avoiding undesirable agitation resistance during the blending of the suspension with other materials. The suspension is thus useful for imparting a benefit or an aroma to a consumable material such as a liquid anionic, cationic, non-ionic or zwitterionic detergent, a shampoo, a bodywash, liquid soaps, hair conditioners, skin lotions, anti-perspirants, deodorants or liquid fabric softener and/or conditioner compositions. Also described is a process for preparing such stable suspensions and apparatus for carrying out such process.

  本发明涉及一种稳定的初始冲击和连续冲击香气和/或效益剂-传递微囊化香气和/或效益剂的水悬浮液，例如，恶臭对抗剂悬浮在非限制香气含量和/或效益剂含量的液相油包水乳化液中。在储存过程中，悬浮液的粘度在长时间内仅略微增加，从而避免了在将悬浮液与其他材料混合时产生不良的搅拌阻力。因此，该悬浮液可用于向可消费材料（例如液体阴离子、阳离子、非离子或双性洗涤剂、洗发水、沐浴露、液体肥皂、护发素、皮肤乳液、止汗剂、除臭剂或液体柔顺剂和/或调理剂组成）传递效益或香气。还描述了一种制备这种稳定悬浮液的方法和用于执行这种方法的设备。
• Stable Fragrance microcapsule suspension and process for using same
  申请人：INTERNATIONAL FLAVORS & FRAGRANCES INC.

  公开号：EP1589092A1

  公开（公告）日：2005-10-26

  Described is a stable initial impact and continuous impact fragrance and/or benefit agent- imparting aqueous suspension of microencapsulated fragrance and/or benefit agent, e.g., malodour counteractant suspended in a non-confined fragrance-containing and/or benefit agent-containing liquid phase oil-in-water emulsion. On storage, the viscosity of the suspension undergoes a minimal increase over an extended period of time thereby avoiding undesirable agitation resistance during the blending of the suspension with other materials. The suspension is thus useful for imparting a benefit or an aroma to a consumable material such as a liquid anionic, cationic, non-ionic or zwitterionic detergent, a shampoo, a bodywash, liquid soaps, hair conditioners, skin lotions, antiperspirants, deodorants or liquid fabric softener and/or conditioner compositions. Also described is a process for preparing such stable suspensions and apparatus for carrying out such process.

  所述的是一种稳定的初始影响和持续影响香味和/或益效剂的水性悬浮液，该悬浮液由微胶囊化的香味和/或益效剂（如恶臭抑制剂）组成，悬浮于非封闭的含香味和/或益效剂的液相水包油型乳液中。在储存过程中，悬浮液的粘度在较长时间内的增加幅度很小，从而避免了在悬浮液与其他材料混合时出现不理想的搅拌阻力。因此，该悬浮液可用于向液体阴离子、阳离子、非离子或齐聚物洗涤剂、洗发水、沐浴露、液体肥皂、护发素、护肤乳液、止汗剂、除臭剂或液体织物柔软剂和/或护理剂组合物等消耗材料中添加益处或香味。此外，还介绍了制备这种稳定悬浮液的工艺和实施这种工艺的设备。
• Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12
  作者：Dennis A. Holt、Juan I. Luengo、Dennis S. Yamashita、Hye Ja Oh、Arda L. Konialian、Hwa Kwo Yen、Leonard W. Rozamus、Martin Brandt、Mary J. Bossard、Mark A. Levy、Drake S. Eggleston、Jun Liang、L. Wayne Schultz、Thomas J. Stout、Jon Clardy

  DOI：10.1021/ja00075a008

  日期：1993.11.1

  The design and synthesis of high-affinity FKBP12 ligands is described. These compounds potently inhibit the cis-trans-peptidylprolyl isomerase (rotamase) activity catalyzed by FKBP12 with inhibition constants (K(i,app)) as low as 1 nM, yet they possess remarkable structural simplicity relative to FK506 and rapamycin, from which they are conceptually derived. The atomic structures of three FKBP12-ligand complexes and of one unbound ligand were determined by X-ray crystallography and are compared to the FKBP12-FK506 and FKBP12-rapamycin complexes.
• FLIPPIN, LEE A.;GALLAGHER, DAVID W.;JALALI-ARAGHI, KEYVAN, CHEM. RES. (S),(1988) N1, C. 1430-1432
  作者：FLIPPIN, LEE A.、GALLAGHER, DAVID W.、JALALI-ARAGHI, KEYVAN

  DOI：——

  日期：——
• [EN] LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS<br/>[FR] CONJUGUÉS DE LIGANDS POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUEMENT ACTIFS
  申请人：[en]HEPAGENE THERAPEUTICS (HK) LIMITED

  公开号：WO2023011597A1

  公开（公告）日：2023-02-09

  Provided are compounds of Formula (I) as novel ligand conjugates, and use thereof for delivering therapeutically active agents. The compounds have the advantages for in vitro and/or in vivo delivery of therapeutically active agents, e.g., iRNA agents.